Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
1.600
+0.050 (3.23%)
At close: Feb 11, 2026, 4:00 PM EST
1.618
+0.018 (1.13%)
After-hours: Feb 11, 2026, 7:51 PM EST
Cardiff Oncology Employees
As of December 31, 2024, Cardiff Oncology had 33 total employees, including 32 full-time and 1 part-time employees. The number of employees increased by 1 or 3.13% compared to the previous year.
Employees
33
Change (1Y)
1
Growth (1Y)
3.13%
Revenue / Employee
$15,182
Profits / Employee
-$1,528,667
Market Cap
107.78M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 33 | 1 | 3.13% | 32 | 1 |
| Dec 31, 2023 | 32 | 6 | 23.08% | 31 | 1 |
| Dec 31, 2022 | 26 | 3 | 13.04% | 25 | 1 |
| Dec 31, 2021 | 23 | 11 | 91.67% | 22 | 1 |
| Dec 31, 2020 | 12 | -2 | -14.29% | 11 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 341 |
| Agenus | 316 |
| Seer, Inc. | 134 |
| Vivani Medical | 37 |
| Cassava Sciences | 30 |
| Cognition Therapeutics | 28 |
| Genelux | 24 |
| Dogwood Therapeutics | 12 |
CRDF News
- 14 days ago - Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus - Benzinga
- 14 days ago - Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript - Seeking Alpha
- 15 days ago - Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC - GlobeNewsWire
- 15 days ago - Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development - GlobeNewsWire
- 4 weeks ago - Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm - Seeking Alpha
- 2 months ago - Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 - GlobeNewsWire
- 2 months ago - Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference - GlobeNewsWire
- 2 months ago - Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire